TCDD and omeprazole prime platelets through the aryl hydrocarbon receptor (AhR) 
Introduction
The aryl hydrocarbon receptor (AhR) is a highly conserved ligand-dependent transcription factor, belonging to the helix loop helix/PAS family of receptors. It is involved in detoxification pathways, and activation results in transcription of several xenobiotic response elements, including CYP1A1 and CYP1B1 (Barouki et al., 2007) . AhR ligands include dioxins, furans, polychlorinated byphenyls, tryptophan metabolites and benzimidazoles (Denison and Nagy, 2003) . Many of these chemicals are environmentally persistent organic molecules, which represent a high risk to humans (Steenland et al., 2004) . The halogenated aromatic hydrocarbon 2, 3, 7, is the most potent AhR ligand. Adverse effects resulting from TCDD exposure include developmental and reproductive toxicity, hepatic toxicity, tumor development, wasting syndrome and death (Fernandez-Salguero et al., 1996; Mimura and Fujii-Kuriyama, 2003) . Omeprazole, a benzimidazole derivative, is a proton pump inhibitor used for the suppression of gastric acid secretion (Clissold and Campoli-Richards, 1986) . It also is a recognized AhR activator, as evidenced by its ability to induce CYP1A1, CYP1B1 and other AhR-regulated genes (Jin et al., 2012; Shivanna et al., 2011) , and is used to study the role of the AhR in cell differentiation, metastasis, inflammation and other biological processes (Jin et al., 2014) .
Two AhR pathways have been characterized; the classical (genomic) pathway and the non-genomic pathway. In the classical pathway, upon ligand binding, the AhR translocates to the nucleus and heterodimerizes with the AhR nuclear translocator (ARNT) which initiates transcription of xenobiotic-responsive elements (Tompkins and Wallace, 2007) . A second pathway, the AhR nongenomic pathway, does not involve translocation of the AhR to the nucleus, but instead results in a cascade of signaling events including phosphorylation of mitogen activated protein kinases (MAPKs), cytosolic phospholipase A 2 (cPLA 2 ) activation, increases in intracellular calcium, release of arachidonic acid (AA) and induction of inflammatory mediators (Matsumura, 2009) . In nucleated cells, this pathway has been studied by mutating the AhR nuclear localization sequence thereby preventing AhR nuclear translocation (Vogel et al., 2007) , as well as siRNA, blocking the formation of AhR/ARNT heterodimers required for initiation of transcription of xenobiotic response elements Sciullo et al., 2008) .
Platelets, anucleate cells, circulate in a resting state in the vasculature. Vascular injury results in platelet activation characterized by granule release, interaction with coagulation factors and the formation of a hemostatic plug. This process is highly regulated as sporadic activation can result in inappropriate thrombus formation, development of emboli, and eventual occlusion of critical blood vessels resulting in heart attack or stroke (Brass, 2003) . Resting platelets can be primed for activation, such that they are more sensitive to physiological agonists. These primed platelets have an enhanced response to stimuli, and represent a risk for potential pathological thrombus formation and vessel occlusion (Gresele et al., 2008) . A number of molecules prime platelets, and many manifest their activity by initiating intracellular signaling cascades (Blair et al., 2014; Falcinelli et al., 2005; Kowalska et al., 1994; Vezza et al., 1993) . These priming events lead to circulating platelets that are more excitable, and who have increased responses to physiologic activation.
A recent study of the effects of TCDD on zebrafish thrombocytes, suggests a role for AhR signaling and the induction of thrombocyte activation (Kim et al., 2015) . Studies by Lindsey et al. (2014) documented that AhR null mouse platelets have defective collagen mediated activation, as well as lower numbers of circulating platelets and increased bleeding times (Lindsey and Papoutsakis, 2011) . These studies provide evidence for the emerging role of the AhR in platelet activation; yet the human platelet AhR signaling pathway remains to be defined.
Herein we describe the human platelet AhR non-genomic pathway and demonstrate that incubation with TCDD or omeprazole results in increased AhR protein synthesis, in the absence of increased AhR mRNA. We also show that binding of activator to the AhR initiates downstream signaling through the p38MAPK/cPLA 2 pathway, resulting in platelet priming as demonstrated by enhanced platelet aggregation in response to the thrombin receptor agonist SFLLRN.
Materials and methods

Volunteers
Samples were obtained from healthy volunteers between the ages of 18 and 65, who had not taken aspirin or any other nonsteroidal anti-inflammatory medication for at least 2 weeks prior to donation; following approved protocol (299969-3) by the Institutional Review Board of the University of California, Davis. All human volunteers provided a signed consent.
Platelet preparation
Blood samples were collected in either citrate-dextrose solution (ACD-A) or sodium citrate and stored at 37 C for up to 1 h prior to use. Platelet-rich plasma (PRP) was obtained by centrifuging whole blood (325 Â g, 15 min RT). Washed platelets were prepared by centrifugation of PRP (with the addition of 10 mg/ml of PGE 1 ) (500 Â g, 24 min), and the resulting platelet pellet suspended in Tyrode's-HEPES (12 mM NaHCO 3 , 138 mM NaCl, 2.9 mM KCl, 10 mM HEPES, 500 mM dextrose, pH 7.2). Platelet counts were adjusted to 2 Â 10 8 cells/ml for all experiments, unless otherwise noted.
Aggregometry
PRP was generated as described above. Platelet concentrations for all aggregometry experiments were !2 Â 10 6 cells/ml. PRP samples were pre-incubated with dimethyl sulfoxide (DMSO, vehicle control, Sigma-Aldrich), 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (gift from Dr. Michael Dennison, University of California, Davis) or omeprazole (Sigma-Aldrich) (1 h; 37 C). Platelets were then stimulated with the protease-activated receptor 1 (PAR-1)(thrombin receptor) activator pepide SFLLRN (10 mM) (Trocris Bioscience, Bristol, UK), and aggregation measured by optical aggregometry (Model 490ChronoLog Corporation, Havertown, PA). Slope and amplitude were calculated using ChronoLog software.
Western blots
Washed platelets were incubated with DMSO, TCDD or omeprazole (37 C; 1 h) or SFLLRN (37 C; 10 min). Samples were lysed in SDS-PAGE buffer, in the presence of protease inhibitors (leupeptin, pepstatin, trypsin inhibitor soybean, AESBSF and EDTA (Calbiochem, La Jolla, CA)), aprotinin (Sigma-Aldrich, St. Louis) and phosphatase inhibitors (Halt Phosphatase Inhibitor Cocktail, Thermo Fisher Scientific, Rockford, IL). Samples were separated by SDS-PAGE, transferred to nitrocellulose membranes, blocked with 5% (w/v) dry non-fat milk in Tris-buffered saline-Tween 20 (TBST), and incubated overnight (4 C) with the one of the following antibodies: AhR monoclonal (A-3, Santa Cruz Biotechnology, Santa Cruz, CA), p38MAPK polyclonal, monoclonal phospho-p38MAPK, polyclonal total cPLA 2 , polyclonal phosphocPLA 2 or beta-actin (Cell Signaling Technology, Danvers, MA). Membranes were washed in TBST and incubated with either an anti-mouse (Santa Cruz Biotechnology) or anti-rabbit (Cell Signaling Technology) horseradish peroxidase conjugated antibody (1 h). Immunoblots were visualized by chemiluminescence (Super Signal West Femto Maximum Sensitivity Substrate, Thermo Fisher Scientific), according to manufacturer's protocol. Images were captured using Protein Simple FluorChem E System (Protein Simple, Santa Clara, CA) and densitometry was performed using Alpha View software, from Protein Simple. Beta actin served as a loading control. Blots were quantified by densitometry using either total p38MAPK or total cPLA 2 to evaluate relative phosphorylation.
Inhibition studies
Washed platelets or PRP were incubated with the competitive AhR antagonists alpha naphthoflavone (aNF, 5 mM) or CH-223191 (CH, 10 mM) (Sigma-Aldrich) concomitantly with TCDD (1 h; 37 C). Samples were then prepared for western blot analysis or aggregometry as described above. p38MAPK inhibition of washed platelets was conducted with SB 292190 (SB, 20 mM) (Sigma-Aldrich) (10 min), followed by the addition of TCDD (1 nM) or omeprazole (100 nM) (1 h; 37 C). To inhibit protein translation, washed platelets were incubated with puromycin (In VivoGen-San Diego, CA), (2 h; 37 C); followed by the addition of DMSO, TCDD (1 nM) or omeprazole (100 nM) (1 h; 37 C).
Calcium measurement
PRP was generated as described above, diluted in 50% Tyrode'sHepes buffer and incubated for 60 min with Fluo-4 NW (37 C) (Invitrogen, Carlsbad, CA) per the manufacturer's instructions. To determine immediate effect of omeprazole on calcium levels, omeprazole (10 nM, 100 nM) was added to Fluo 4-NW loaded PRP and relative fluorescence was measured for 250 s.
To determine if longer incubation with omeprazole (1 h) altered relative calcium levels, omeprazole or DMSO were added concomitantly with Fluo-4NW, samples were incubated (37 C; 1 h) and relative fluorescence measured. Additional aliquots were stimulated with SFLLRN (10 mM) and relative fluorescence was measured for 250 s. TCDD was not examined due to the significant risk of exposure.
All samples were read in a 96 well plate, and baseline relative fluorescence for each well was measured prior to stimulation or omeprazole addition; each condition was run in duplicate. Fluorescence was measured using a Synergy HT Multi-Mode microplate reader with Gen5 software (Biotek, Winooski, VT). Fig. 1 . Characterization of human platelet AhR: TCDD or omeprazole incubation results in a dose dependent increase in AhR expression. Washed platelets were incubated for 1 h with TCDD (0.01, 0.1 and 1 nM) (A) or omeprazole (1, 10 and 100 nM) (B). Cell lysates were probed for AhR, and results expressed as fold changes relative to the vehicle control. There is a significant increase in AhR expression in response to both TCDD (1 nM) (A) and omeprazole (10 and 100 nM) (B). Representative results, n = 4. qRT-PCR products were run on an agarose gel, and compared with AhR message from THP-1 cells (positive control) (C).
Washed platelets were incubated with puromycin (20 mM) (2 h), prior to incubation with TCDD (1 nM) or omeprazole (100 nM) (D). Cell lysates were probed for AhR.
Representative results, n = 3.-!>
RNA isolation and quantitative RT PCR anlaysis
Washed platelets were further purified by removal of contaminating red or white blood cells following a modification of the method by Amisten (2012) . Washed platelet suspensions were incubated with CD235a and CD45 (mouse anti-human; BD Pharmigen, Franklin Lakes, NJ) antibody coated magnetic beads (Dynabeads-Pan Mouse IgG; Life Technologies, Grand Island, NY) (2 h) to immuno-deplete residual red blood cells and leukocytes (respectively). Purified platelet suspensions were dissolved in TRIzol (Life Technologies); the aqueous layer from the previous extraction was added to an equal volume of 70% ethanol and RNA was extracted using RNeasy Mini Kit (Qiagen, Valencia, CA), according to manufacturer's instructions. cDNA was synthesized from isolated RNA using Superscript III and random primers (Invitrogen-Life Technologies). To examine AhR mRNA expression in human platelets, qRT PCR was performed using the AhR forward primer: TCCACCTAGTTGGTTTGTTTGC, reverse primer: TCGTGCA-CAGCTCTGCTTCAGTAT designed with Integrated DNA Technologies (IDT online software). cDNA from cultured THP-1 cells, a human monocytic cell line shown to have mRNA for AhR (Komura et al., 2001) , was used as a positive control. Products of the PCR reaction were loaded on a 2% agarose gel for visualization. Amplicon size was confirmed using GeneRuler 100 bp Plus DNA Ladder (Thermo Fisher Scientific). To evaluate the relative changes in mRNA expression, purified platelet suspensions were incubated with DMSO or TCDD (1 nM) (1 h; 37 C); RNA isolated and cDNA synthesized, as described above. AhR mRNA expression was measured and normalized to beta actin using the forward primer: CTGTCCACCTTCCAGCAGATGT, reverse primer: CGCAACTAAGTCA-TAGTCCGCC. Real-time PCR assays were performed in triplicate with SYBR Green PCR MasterMix (Applied Biosystems, Warrington, Washed platelets were incubated for 1 h with one of two AhR competitive inhibitors: aNF (5 mM) or CH (10 mM), concomitant with TCDD (1 nM) (C). Cell lysates were probed for phospho-p38MAPK and total p38MAPK. Treatment with either inhibitor results in a significant decrease in phosphorylation of p38MAPK. Representative results, n = 4. UK) on an Applied Biosystems 7300 Real-time PCR System. The cycling conditions were as follows: 50 C for 2 min, 95 C for 10 min followed by 40 cycles of 95 C for 15 s, and 60 C for 1 min. All realtime PCR assays were followed by a dissociation step (melt curve). The comparative threshold cycle (Ct) method was used to calculate relative changes in gene expression determined from real-time quantitative PCR experiments (7300 system software, Applied Biosystems).
Statistical analyses
Data that were normally distributed were analyzed either by paired t-test or ANOVA. Data that were not normally distributed were analyzed by Wilcoxon signed rank test or Friedman test. A p value <0.05 was considered to be statistically significant (GraphPad Prism 6.0). (*p < 0.05, **p < 0.01)
Results
Characterization of the human platelet AhR
To determine the human platelet AhR response to TCDD or omeprazole, washed human platelets were incubated with increasing concentrations of AhR activator, and AhR protein expression measured by western blot. Our data showed that AhR protein expression levels increased with increasing doses of either TCDD or omeprazole (Fig. 1A and B) , and were statistically significant for both TCDD (1 nM) and omeprazole (10 nM and 100 nM).
Platelets are anucleate cells, however, they contain mRNA and functional machinery for protein synthesis (Zimmerman and Weyrich, 2008) . Our western blot results demonstrated increased levels of AhR protein in response to activators, thus we wanted to determine whether there were changes in mRNA levels in response to TCDD. Using qRT-PCR, we determined that human platelets had AhR mRNA. To visually confirm that our amplicon product was the correct size (155 bp), qRT-PCR reaction products were run on an agarose gel, using THP-1 cell cDNA as a positive control (Komura et al., 2001) (Fig. 1C) . Platelet incubation with TCDD did not alter mRNA expression levels (DDCt: 1.01, n = 3), suggesting that the AhR protein increase observed after incubation with TCDD was likely the result of protein translation. Incubation of platelets with the protein translation inhibitor puromycin, prior to the addition of TCDD or omeprazole, resulted in attenuation of the AhR protein increase previously seen after incubation with either activator (Fig  1D) .
Ligand dependent downstream signal transduction
To characterize the downstream signaling of the AhR nongenomic pathway, we evaluated phosphorylation of p38MAPK, an important molecule in multiple platelet activation pathways Fig. 3 . TCDD and omeprazole induce cPLA 2 phosphorylation downstream of p38MAPK. Washed platelets were incubated for 1 h with TCDD (0.01, 0.1 and 1 nM) or omeprazole (1,10 and 100 nM) (A) and probed for phospho-cPLA 2 and total cPLA 2 . Densitometry measurements are shown as fold change relative to vehicle control. There is a statistically significant increase in phosphorylation of cPLA 2 in response to TCDD (1 nM) and omeprazole (100 nM). Representative results, n = 4. Washed platelets were incubated with the p38MAPK inhibitor SB for 10 min, followed by incubation in TCDD (1 nM) or omeprazole (10 and 100 nM) (1 h) (B). Lysates were probed for phospho-cPLA 2 and total cPLA 2 . Virtually no phosphorylation of cPLA 2 was observed. Representative results, n = 3. (Kramer et al., 1996; Kuliopulos et al., 2004) , and a protein shown to be involved in AhR non-genomic signaling (Henklova et al., 2008) . Platelets incubated with increasing concentrations of AhR activators, TCDD (1 nM) or omeprazole (10 nM and 100 nM) resulted in statistically significantly increased p38MAPK phosphorylation ( Fig. 2A and B) . To confirm that p38MAPK phosphorylation was dependent on AhR ligand binding, washed platelets were incubated with one of two competitive AhR antagonists, aNF or CH (Denison and Nagy, 2003) in the presence of TCDD. Our results demonstrated a statistically significant decrease in p38MAPK phosphorylation under these conditions (Fig. 2C) .
In platelet activation, p38MAPK activation is associated with downstream cPLA 2 phosphorylation (Kramer et al., 1996) ; thus we wished to determine the effects of TCDD and omeprazole on cPLA 2 phosphorylation. Platelets incubated with increasing concentrations of TCDD or omeprazole had a statistically significant dose dependent increase in cPLA 2 phosphorylation (1 nM TCDD and 100 nM omeprazole) (Fig. 3A) . To confirm that cPLA 2 phosphorylation was dependent on p38MAPK phosphorylation, platelets were incubated with the p38MAPK specific inhibitor SB (Wilson et al., 1997) . cPLA 2 phosphorylation was absent in platelets incubated with SB compared to platelets incubated only with AhR activator (Fig. 3B) .
In platelets, agonist stimulation results in a rapid rise in intracellular calcium, which is essential for platelet activation (Detwiler et al., 1978) . We wished to determine if omeprazole would have a similar effect on intracellular calcium. Intracellular calcium levels, determined by changes in relative fluorescence emission, were measured in Fluo-4 loaded platelets. PRP incubated with omeprazole had comparable relative fluorescence levels to PRP incubated with DMSO vehicle control (Relative Fluorescence Units (RFU) DMSO: 13,002 AE 1028; 10 nM omeprazole: 12,857 AE 688.3; 100 nM omeprazole: 13,269 AE 804.3; p = 0.4306) (Fig. 4A) . Calcium increases resulting from stimulation with SFLLRN were not significantly enhanced by pre-incubation of PRP with either 10 nM or 100 nM omeprazole, compared with a DMSO control (area under the curve (AUC) DMSO: 4.037e + 006 AE 368,666; 10 nM omeprazole: 4.065e + 006 AE 407,499; 100 nM omeprazole: 4.040e + 006 AE 375,221; p ! 0.999) (Fig. 4B) . The initial addition of omeprazole did not result in a transient calcium rise (Fig. 4C) .
Platelet priming
Platelet priming, defined as an increased sensitivity to physiologic agonists, can be evaluated by aggregometry. PRP was incubated with control vehicle, TCDD or omeprazole, then stimulated with SFLLRN and activation measured by optical aggregometry. Our results showed that samples incubated with either AhR activator had increased platelet aggregates as evidenced by a decrease in optical absorbance (Fig. 5A and B) . The rates of aggregation (slope) and the percent maximum aggregation (amplitude) were statistically significantly greater than controls. Treatment of PRP with the AhR antagonist aNF (Fig. 5C ), or the p38MAPK inhibitor SB (data not shown; p < 0.05), significantly inhibited the priming effects of TCDD.
Platelet stimulation by physiologic agonist can induce protein synthesis of a number of signaling proteins (Zimmerman and Weyrich, 2008) . Our results showed that incubation with AhR activator resulted in increased AhR protein levels (Fig. 1) . Thus we wished to know if platelet stimulation with SFLLRN would result in increased AhR protein expression. We found that AhR expression was not up-regulated after incubation with SFLLRN (10 mM, 20 mM or 40 mM) (Fig. 6) .
Discussion
Our study describes the AhR non-genomic pathway in human platelets, and demonstrates that platelets have mRNA for AhR, and that AhR protein is increased when platelets are incubated with the AhR activators TCDD or omeprazole. Platelets are anucleate cells, yet several laboratories have demonstrated the physiologic relevance of protein translation in platelet activation (Zimmerman and Weyrich, 2008) . Platelet stimulation with the physiological agonist thrombin induces synthesis of proteins such as Bcl-3, an important protein in integrin dependent platelet activation, and Il1b, a pro-inflammatory cytokine secreted after platelet stimulation (Lindemann et al., 2001; Weyrich et al., 1998) . We show that incubation with the AhR activators TCDD or omeprazole is sufficient to induce increased AhR protein synthesis, which is Incubation of human platelets with AhR activators results in a dose and AhR dependent increase in p38MAPK phosphorylation. During physiologic activation by agonists such as thrombin and SFLLRN, p38MAPK is phosphorylated and plays an important role in platelet signaling (Kuliopulos et al., 2004) . Activation of p38MAPK in the AhR non-genomic pathway appears to be cell type-specific. In rat hepatoma cells, incubation with TCDD results in AhR dependent p38MAPK phosphorylation (Weiss et al., 2005 ), yet, in murine macrophages, TCDD induced p38MAPK activation was independent of the AhR (Park et al., 2005) .
We show that incubation with TCDD or omeprazole results in cPLA 2 phosphorylation, which is dependent on p38MAPK. During platelet activation, cPLA 2 phosphorylation is downstream of p38MAPK, and its activation mediates movement of AA from the plasma membrane to the cytosol (Kramer et al., 1996) . cPLA 2 also can be transiently activated by increases in intracellular calcium (Leslie et al., 2010) . In the AhR non-genomic pathway, incubation with AhR activator results in transient cPLA 2 phosphorylation which is associated with a rise in intracellular calcium (Dong et al., 2010; Li and Matsumura, 2008; Sciullo et al., 2008) . However, in human platelets, treatment with omeprazole did not alter intracellular calcium levels. Our results suggest that in human platelets, transient cPLA 2 phosphorylation via the AhR nongenomic pathway is primarily mediated by p38MAPK.
Platelet activation initiates signaling events culminating in granule secretion, platelet aggregation and the development of a pro-coagulant environment (Brass, 2003) , critical for the development of a physiologically stable thrombus (Jarvis, 2004) . Platelets incubated with AhR activators and subsequently stimulated with SFLLRN showed enhanced platelet aggregation, suggesting that binding these AhR activators to the AhR prime platelets. Platelet priming occurs when cells are exposed to a compound that by itself does not induce activation, but which leads to an enhanced cellular response to physiological stimuli (Gresele et al., 2008) . PRP was incubated for 1 h with DMSO or TCDD (1 nM) (A) or omeprazole (100 nM) (B) followed by activation with SFLLRN (10 mM) and platelet activation measured by optical aggregometry. Representative aggregometry curves, n = 4.
PRP was incubated for 1 h with aNF concomitantly with TCDD (1 nM) (C), followed by activation with SFLLRN (10 mM). Platelet aggregation measured by optical aggregometry.
Representative aggregometry curves n = 5. ANF significantly decreases enhanced platelet aggregation. Washed platelets were stimulated with increasing doses of the SFLLRN (10 mM, 20 mM or 40 mM) (10 mins). Cell lysates were probed for AhR. There was no change in protein expression in response to SFLLRN stimulation. Representative results, n = 3. Several molecules prime platelets by initiating signaling prior to physiological agonist stimulation. Platelet derived PGE 2 , matrix metalloproteinase-2 (MPP-2), insulin-like growth factor 1 (IGF-1), and histamine potentiate platelet responses by modulating signaling proteins such as protein kinase C (PKC), phosphatidylinositol 3-kinase (PI3-K) and p38MAPK respectively. (Blair et al., 2014; Falcinelli et al., 2005; Shah et al., 2000; Vezza et al., 1993) . Our study shows that activation of the AhR leads to phosphorylation of p38MAPK and transient activation of cPLA 2 resulting in platelet priming.
Our studies may shed light on the current clinical conundrum regarding the combined therapeutic use of omeprazole and the platelet purinergic receptor inhibitor clopidogrel. Clopidogrel, a prodrug metabolized by cytochrome P450s, is frequently prescribed together with omeprazole, to prevent gastrointestinal bleeding. Importantly, several reports suggest that in patients receiving this combined therapy, clopidogrel's efficacy is diminished (Gilard et al., 2006; Pezalla et al., 2008) . This decrease in clopidogrel's function is thought to be due to omeprazole's competitive inhibition of the CYP450 isoenzyme group (Cuisset et al., 2009; Gilard et al., 2008) . Our data suggests an alternative scenario, in which omeprazole therapy, modulating platelet priming through the AhR, could upregulate platelet activation, resulting in a diminished response to clopidogrel therapy.
Overall, our data add to the increasing body of knowledge regarding the role of the AhR in platelet biology. Further studies are required to expand our understanding of the role of the human platelet AhR in hemostasis and thrombosis.
Conflict of interest
The authors declare that there are no conflicts of interest.
Transparency document
The Transparency document associated with this article can be found in the online version.
